Department of Integrative Gastroenterology, Faculty of Medicine, University of Duisburg-Essen, Germany Department of Internal and Integrative Medicine, Faculty of Medicine, University of Duisburg-Essen, Germany
Department of Internal and Integrative Medicine, Faculty of Medicine, University of Duisburg-Essen, Germany.
J Crohns Colitis. 2015 Jan;9(1):86-106. doi: 10.1093/ecco-jcc/jju007. Epub 2014 Nov 28.
We performed a systematic review for Complementary and Alternative Medicine [CAM] as defined by the National Institute of Health in Inflammatory Bowel Disease [IBD], ie Crohn's disease [CD] and ulcerative colitis [UC], with the exception of dietary and nutritional supplements, and manipulative therapies.
A computerized search of databases [Cochrane Library, Pubmed/Medline, PsychINFO, and Scopus] through March 2014 was performed. We screened the reference sections of original studies and systematic reviews in English language for CAM in IBD, CD and UC. Randomized controlled trials [RCT] and controlled trials [CT] were referred and assessed using the Cochrane risk of bias tool.
A total of: 26 RCT and 3 CT for herbal medicine, eg aloe-vera gel, andrographis paniculata, artemisia absinthium, barley foodstuff, boswellia serrata, cannabis, curcumin, evening primrose oil, Myrrhinil intest®, plantago ovata, silymarin, sophora, tormentil, wheatgrass-juice and wormwood; 1 RCT for trichuris suis ovata; 7 RCT for mind/body interventions such as lifestyle modification, hypnotherapy, relaxation training and mindfulness; and 2 RCT in acupuncture; were found. Risk of bias was quite heterogeneous. Best evidence was found for herbal therapy, ie plantago ovata and curcumin in UC maintenance therapy, wormwood in CD, mind/body therapy and self-intervention in UC, and acupuncture in UC and CD.
Complementary and alternative therapies might be effective for the treatment of inflammatory bowel diseases; however, given the low number of trials and the heterogeneous methodological quality of trials, further in-depth research is necessary.
我们对美国国立卫生研究院(NIH)定义的炎症性肠病(IBD),即克罗恩病(CD)和溃疡性结肠炎(UC)中的补充和替代医学(CAM)进行了系统评价,除了饮食和营养补充剂以及手法治疗。
通过 2014 年 3 月对数据库(Cochrane 图书馆、Pubmed/Medline、PsychINFO 和 Scopus)进行计算机检索,我们筛选了英文 IBD、CD 和 UC 中 CAM 的原始研究和系统评价的参考文献部分。使用 Cochrane 偏倚风险工具对随机对照试验(RCT)和对照试验(CT)进行评估。
共发现:26 项草药医学 RCT 和 3 项 CT,例如芦荟凝胶、穿心莲、苦艾、大麦食品、乳香、大麻、姜黄素、月见草油、Myrrhinil intest®、车前子、水飞蓟素、苦参、仙鹤草和艾草;1 项 Trichuris suis ovata RCT;7 项身心干预 RCT,如生活方式改变、催眠疗法、放松训练和正念;2 项针刺 RCT。偏倚风险相当异质。发现最好的证据是草药疗法,即在 UC 维持治疗中车前子和姜黄素、CD 中的艾草、UC 中的身心疗法和自我干预以及 UC 和 CD 中的针刺。
补充和替代疗法可能对治疗炎症性肠病有效;然而,鉴于试验数量较少且试验方法学质量存在差异,需要进一步深入研究。